Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Copper Miners ETF (COPX) vs Mesoblast Limited (MESO) Price & Performance

Global X Copper Miners ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Global X Copper Miners ETF vs Mesoblast Limited — how do they compare? Global X Copper Miners ETF trades at $78, while Mesoblast Limited trades at $17.61 (market cap $2.12B). Which is the better fit depends on your goals.

COPXMESO
Sector
Commodities - Metals/AgricultureTechnology
52-Week High
$95.70$20.96
52-Week Low
$42.75$10.96
Market Cap
$2.12B
Enterprise Value
$2.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Copper Miners ETF

COPX (Global X Copper Miners ETF) trades at $74.35, down 2.86% amid bearish technical signals with all 16 moving average indicators signaling sell. The ETF provides exposure to copper mining companies benefiting from AI-driven electrification demand, though key financial ratios remain undisclosed in current data. Recent news highlights copper's structural role in AI infrastructure and energy transition.

Outlook hinges on copper supply-demand dynamics amplified by AI data center expansion, though technical weakness suggests near-term pressure. Risks include commodity price volatility and execution challenges in mining supply chains. Analyst sentiment remains constructive on long-term copper fundamentals despite current bearish technical positioning.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Copper Miners ETF

COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.

Read more on COPX

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO